ICU Medical (NASDAQ: ICUI) reported Q2 EPS of $1.56, $0.56 better than the analyst estimate of $1.00. Revenue for the quarter came in at $596.5 million versus the consensus estimate of $553.74 million.

GUIDANCE:

ICU Medical sees FY2024 EPS of $4.95-$5.35, versus the consensus of $4.83.

For Fiscal Year 2024 the Company updated its estimates of GAAP net loss from a range of $(127) to $(110) to a range of $(118) to $(108) and GAAP diluted loss per share from a range of $(5.16) to $(4.46) to a range of $(4.78) to $(4.38). The Company updated the estimate of the range of its full year 2024 guidance of adjusted EBITDA from a range of $330 million to $370 million to a range of $345 million to $365 million.

For earnings history and earnings-related data on ICU Medical (ICUI) click here.